Freshfields LLP has advised argenx. Wilson Sonsini Goodrich & Rosati, P.C. has advised Forte Biosciences. Argen NV ADR (NASDAQ: ARGX) and Forte Biosciences, Inc. (NASDAQ: FBRX)...
argenx Acquires Forte Biosciences for $2.2 Billion, Adding First-in-Class Anti-CD122 Antibody to Immunology Pipeline
Forte Biosciences Announces $150 Million Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences. Paul Hastings LLP has advised Guggenheim Securities and Barclays. Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing...
Forte Biosciences Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences, Inc. on the offering, and Paul Hastings has advised the underwriters. Forte Biosciences, Inc., a clinical-stage biopharmaceutical...
Forte Biosciences’ $53 Million Equity Financing
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences, while Paul Hastings advised TD Cowen in the transaction. Biopharmaceutical company, Forte Biosciences, announced an oversubscribed $53 million...
Forte Biosciences’ $25 Million Financing
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. Forte Biosciences (NASDAQ: FBRX) announced key R&D updates for its product candidate FB-102 (a proprietary molecule...